Pharma Fridays – December 6, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric […]

To view the full Member Resource, please Log in


TOPICS IN THIS ARTICLE:

Share this article